Clotrimazole 1% addition to antifungal monograph requested by Schering-Plough.
This article was originally published in The Tan Sheet
Executive Summary
CLOTRIMAZOLE 1% ADDITION TO ANTIFUNGAL MONOGRAPH REQUESTED by Schering-Plough HealthCare Products in a Nov. 27 citizen petition. The firm is requesting that FDA revise the final monograph for topical antifungal OTC drug products to include clotrimazole 1% for the same indications as other imidazole active ingredients: "the treatment of athlete's foot, jock itch and ringworm and for use in the treatment of superficial skin infections caused by yeast (Candida albicans)." The latter indication is for professional labeling only.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC